Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MATIN-2: Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes - A Mechanistic Framework and Phase I/II Protocol Proposal

NCT07610213 is registered in ClinicalTrials.gov with Abdullah Kars as lead sponsor.

NCT NCT07610213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07610213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MATIN-2: Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes - A Mechanistic Framework and Phase I/II Protocol Proposal
Lead sponsor
Abdullah Kars
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
June 1, 2030
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diabetes, type 1 diabetes mellitus, type 1 diabetes mellitus (t1dm)